Invertex Raises $2 Million in Seed Funding Round to Develop Retail Footwear Technology

Media Announcement: Invertex, an early stage Israeli fashion-tech company that delivers cognitive, connected, omnichannel measure-to-fit footwear solutions, announced the closing of its $2 million seed funding round. The round was led by Jerusalem-based equity crowdfunding VC OurCrowd through its OurCrowd First early stage fund. Permoda, an international leading retail & fashion group also participated in the round, together with prominent angel investors.

Invertex is a leading provider of scan-to-fit guided shopping experience platforms that combine advanced 3D-digitization and deep-learning technologies to deliver tailored solutions for in store, at home and online audiences. Invertex’s comprehensive platform enables retailers to significantly improve their online sales-capabilities by lowering returns by empowering customers to trust and enjoy their e-commerce experience. The company’s clients also have the capacity to tailor their existing product lines to their customers’ specific needs.

“We are thrilled to be backed by a renowned lead investor such as OurCrowd First, Israel’s most active early stage venture fund,” said Invertex CEO David Bleicher. “Their investment validates our progress to date and provides us with the required financial strength to accelerate our commercialization efforts, focused on the US Footwear market.”

“Our key partnerships with retail industry leaders coupled with our proven track record in multiple key verticals, positions us as a category maker in the digital convergence of personalized shopping experiences,” concluded Bleicher.

OurCrowd First General partner, Eduardo Shoval, a renowned serial entrepreneur and co-founder of seven successful startups, joined the Invertex board. OurCrowd First was named Israel’s most active early-stage fund for the past two years with 19 hi-tech portfolio investments.

“Invertex was built on the foundation of deep-technology and strong intellectual-property, precisely the ingredients we seek in the companies we invest in,” said Shoval. “David and his team continue to demonstrate outstanding execution and we are thrilled to join the company and accelerate its go to market phase.”

This post was written by:

- who has written 1892 posts on mHealthWatch.


Contact the author

0 comments
Advert